A prior study by Wu et al.34 reported a case of prostate cancer with the SLC45A3 non-coding exon 1 fused to the intact coding region of FGFR2, in which the SLC45A3-FGFR2 fusion was predicted to drive the overexpression of wildtype FGFR2. Thus, the SLC20A2-FGFR1 fusion observed in the current study may also have been able to drive the overexpression of wildtype FGFR1, although additional studies are needed to test this possibility. Here, FGFR2 is linked to prostate cancer.